OCT 21, 2019 10:32 PM PDT

Therapeutic Targets Inflammation Associated with Genetic Heart Disease

WRITTEN BY: Nouran Amin

Often times when young athletes collapse during the game it is due to sudden cardiac death as a result of the inherited arrhythmogenic cardiomyopathy (ACM). Researchers have sought a new drug that can help reduce some of the ACM disease symptoms and progression to heart failure in affected individuals. The drug is referred to as ‘Bay-11-7082’ and is currently used in laboratory settings for experimental purposes.

Learn more:

"We realized that heart muscle inflammation in ACM is much more complicated than we thought, but also might provide a therapeutic strategy," says Stephen Chelko, Ph.D., assistant professor of medicine at the Johns Hopkins University School of Medicine.

ACM patients carry mutations in any of the five genes that are involved with holding the heart cells together. If an individual is aware that they carry such mutations, they are warned to avoid certain exercises and are placed on particular diets. Although some drugs are prescribed to maintain a slower heart rate, there are currently none that target the underlying defects of ACM.

"We tended in the past to view ACM as something that kills due to a sudden arrhythmic event," said Chelko. "But now we're starting to also see it as a chronic inflammatory disease that can progress more slowly over time, leading to heart failure."

Researchers have examined the molecular origins of heart inflammation in people with ACM. Findings, published in Circulation, shows that inflammation is a result of two separate causes: the high levels of an immune cell known as macrophages, a type of immune cell that's normally found at sites of inflammation and the presence of protein nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB).

A healthy mouse heart (left), a mouse heart with cardiomyopathy (center) and a mouse heart with cardiomyopathy treated with the NF-κB-blocking drug Bay-11-7082 (right).

Credit: Circulation via HopkinsMedicine.org

"Macrophages are usually the good guys who help heal a wound and then leave," said Chelko. "But in ACM they're permanently setting up shop in the heart, which, over time, reduces its function. We're very excited to have found an FDA-approved drug that can reduce heart inflammation in ACM, and we're eager to do more research to ultimately help those who carry these genetic mutations.”

Story Source: Johns Hopkins Medicine

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
MAY 18, 2020
Cancer
MAY 18, 2020
How do Ohnologs affect Cancer?
Genetics can be complicated to say the least. Sometimes it can be as simple as a single mutation in one gene that causes ...
MAY 14, 2020
Drug Discovery & Development
MAY 14, 2020
Therapeutic for Gastrointestinal Tumors
The FDA has approved ripretinib (Qinlock) which is the first drug for fourth-line treatment of advanced gastrointestinal ...
JUN 01, 2020
Neuroscience
JUN 01, 2020
What Causes 'Good' and 'Bad' Trips in the Brain
People who use psychedelics like magic mushrooms, LSD and DMT often describe a feeling of going 'beyond their human ...
JUN 02, 2020
Cannabis Sciences
JUN 02, 2020
Ancient Israelites Used Cannabis to Experience God
Researchers have found evidence that ancient worshipers in Israel may have used cannabis to experience God over 2800 yea ...
JUN 15, 2020
Cancer
JUN 15, 2020
Using miRNA to Treat Cancer Stem Cells
In many cancers, there exists a type of cancer cell called a cancer stem cell.  These are cells that, after chemoth ...
JUN 14, 2020
Chemistry & Physics
JUN 14, 2020
Why Are There So Few Black People in STEM?
On June 10th, 2020, thousands of STEM scientists and organizations around the world went on strike to protest systemic r ...
Loading Comments...